A randomized phase III trial, IMpower 150, investigated the efficacy of atezolizumab combined with bevacizumab and chemotherapy in NSCLC, and key subgroup analyses were conducted for patients with EGFR-sensitive mutations (Reck et al., 2019). This evidence concerns the gene EGFR and non-small cell lung carcinoma.